1. Sempowski, G.D., Saunders, K.O., Acharya, P., Wiehe, K.J. & Haynes, B.F. Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. Cell 181, 1458-1463 (2020).
2. Wibmer, C.K., et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv (2021).
3. Wang, Z., et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature (2021).
4. Tada, T., et al. Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. bioRxiv (2021).
5. Wang, P., et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature (2021).
6. Chen, R.E., et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med (2021).
7. Chen, R.E., et al. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature (2021).
8. Callaway, E. & Ledford, H. How bad is Omicron? What scientists know so far. Nature (2021).
9. Torjesen, I. Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ (Clinical research ed 375, n2943 (2021).
10. Johnson, B.A., et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature (2021).
11. Chen, J., Wang, R., Gilby, N.B. & Wei, G.W. Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. ArXiv (2021).
12. Barnes, C.O., et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682-687 (2020).
13. Greaney, A.J., et al. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat Commun 12, 4196 (2021).
14. Pinto, D., et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290-295 (2020).
15. Gupta, A., et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med 385, 1941-1950 (2021).
16. Zost, S.J., et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443-449 (2020).
17. Baum, A., et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science (2020).
18. Starr, T.N., Greaney, A.J., Dingens, A.S. & Bloom, J.D. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell reports. Medicine, 100255 (2021).
19. Gottlieb, R.L., et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. Jama 325, 632-644 (2021).
20. Kim, C., et al. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nat Commun 12, 288 (2021).
21. VanBlargan, L.A., et al. A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. Immunity (2021).
22. Case, J.B., et al. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Cell Host and Microbe 28, 475-485 (2020).
23. Cathcart, A.L., et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv, 2021.2003.2009.434607 (2021).
24. Suryadevara, N., et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell 184, 2316-2331.e2315 (2021).
25. Golcuk, M., Yildiz, A. & Gur, M. The Omicron Variant Increases the Interactions of SARS-CoV-2 Spike Glycoprotein with ACE2. bioRxiv, 2021.2012.2006.471377 (2021).
26. Lempp, F.A., et al. Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. Nature 598, 342-347 (2021).
27. Ford, C.T., Machado, D.J. & Janies, D.A. Predictions of the SARS-CoV-2 Omicron Variant (B.1.1.529) Spike Protein Receptor-Binding Domain Structure and Neutralizing Antibody Interactions. bioRxiv, 2021.2012.2003.471024 (2021).
28. Wilhelm, A., et al. Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies. medRxiv : the preprint server for health sciences, 2021.2012.2007.21267432 (2021).
29. Cao, Y.R., et al. B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes. bioRxiv, 2021.2012.2007.470392 (2021).
30. Cameroni, E., et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv, 2021.2012.2012.472269 (2021).
31. Callaway, E. Omicron likely to weaken COVID vaccine protection. Nature (2021).
32. Cele, S., et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv : the preprint server for health sciences, 2021.2012.2008.21267417 (2021).
33. Dejnirattisai, W., et al. Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum. medRxiv : the preprint server for health sciences, 2021.2012.2010.21267534 (2021).
34. Kim, J.H., Marks, F. & Clemens, J.D. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med (2021).
35. Khoury, D.S., et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 27, 1205-1211 (2021).
36. Schäfer, A., et al. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J Exp Med 218(2021).
37. Zohar, T., et al. Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. Cell 183, 1508-1519.e1512 (2020).
38. Winkler, E.S., et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell 184, 1804-1820.e1816 (2021).
39. Bailey, A.L. & Diamond, M.S. A Crisp(r) New Perspective on SARS-CoV-2 Biology. Cell 184, 15-17 (2021).
40. Lan, J., et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215-220 (2020).